Emerging economies like India and China will increasingly figure among the growth plans of leading multinational pharmaceutical companies, a global survey of top 15 pharma companies carried out by Ernst & Young said.

“The emergence of a middle class with growing disposable incomes in rapidly expanding countries with large populations, such as Brazil, Russia, India, China, Korea, Mexico, represents tens of millions of new customers, who will demand improved healthcare. Executives surveyed discussed the importance of having an emerging market strategy and many mentioned that their companies have extensive expansion plans underway to increase market share in emerging markets,” the report said. Source: Business Standard